Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura. (March 2018)

• Record Type: Journal Article
• Authors: Beckman, Joan D.; Rollins-Raval, Marian A.; Raval, Jay S.; Park, Yara A.; Mazepa, Marshall; Ma, Alice
• Is Part Of: American journal of therapeutics. Volume 25:Number 2(2018)
• Publication Date: 2018-03
• Subjects: immune-mediated thrombocytopenia purpura -- bortezomib; Chemotherapy -- Periodicals; Pharmacology -- Periodicals; 615.58
• DOI: 10.1097/MJT.0000000000000517
• Languages: English
• ISSNs: 1075-2765

Abstract

Abstract : The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.